Pre-eclampsia is a potentially serious condition that affects up to 1 in 20 pregnant people, most often after 20 weeks of pregnancy. Diagnosing pre-eclampsia can be difficult because symptoms and signs differ from person to person. Assessment begins during routine pregnancy appointments, when blood pressure is measured and risk factors for pre-eclampsia are checked. Blood tests have been developed to measure placental growth factor (PlGF), a protein that indicates the function of the placenta. The tests are used along with standard clinical assessment.
This health technology assessment looked at how effective and cost-effective PlGF-based biomarker testing is to help diagnose pre-eclampsia. It also looked at the budget impact of publicly funding PlGF-based biomarker testing and at the experiences, preferences, and values of people with confirmed or suspected pre-eclampsia.
Read the full health technology assessment report for more information.
Placental Growth Factor (PlGF)–Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment
May 2023
Use of this site, and the interpretation of the information contained here, is subject to important terms and conditions. Use of this site and information except in accordance with these terms and conditions is expressly prohibited.
The Ministry of Health is currently reviewing this recommendation.
The Ministry of Health has provided the following response: The Ministry has a standardized process in place to review health technology assessments and funding recommendations. This takes into consideration Ministry priorities, implementation options, the need for consultation with impacted stakeholders, and funding considerations.